THROMBOXAN-REZEPTOR-ANTAGONISTEN

European patent · EP3310756 · In force

Register entry

Publication number
EP3310756
Application number
EP16739541
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 13, 2016
Published
Apr 25, 2018
Granted
Dec 9, 2020
Protection ends at the latest
Jun 12, 2036
Next annual fee due
Jun 30, 2027
IPC classes
C07C 311/58 (2006.01)
A61K 31/277 (2006.01)
A61P 7/02 (2006.01)
Priority
US 201562180317 P 16.06.2015
PCT application
PCT/IB2016/000960 13.06.2016
PCT publication
WO2016/203314 22.12.2016
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Jul 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 01.07.2025

  3. Jul 4, 2024

    Change

    Published in Swissreg on 04.07.2024

  4. Jul 1, 2023

    Change

    Published in Swissreg on 01.07.2023

  5. Jul 6, 2022

    Change

    Published in Swissreg on 06.07.2022

  6. Oct 27, 2021

    Change

    Published in Swissreg on 27.10.2021

  7. Mar 4, 2021

    Agent entered

    Representative
    Novagraaf International SA, Chemin de l'Echo 3, 1213 Onex

    Published in Swissreg on 04.03.2021

  8. Dec 9, 2020

    Granted

    Published in Swissreg on 09.12.2020

Parties

Holder

ATXA Therapeutics Limited

Temple Chambers 3 Burlington Road, Dublin4, D04RD68, IE

Agent

Novagraaf International SA

Chemin de l'Echo 3, 1213 Onex

Inventor

KINSELLA, B., Therese

Blackrock Co. Dublin, IE

REID, Helen

Dublin 13, IE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.